Bevacizumab, sorafenib tosylate, sunitinib and temsirolimus for renal cell carcinoma: a systematic review and economic evaluation

Objectives: To assess the clinical effectiveness and cost-effectiveness of bevacizumab, combined with interferon (IFN), sorafenib tosylate, sunitinib and temsirolimus in the treatment of people with advanced and/or metastatic renal cell carcinoma (RCC). Data sources: Electronic databases, including...

Celý popis

Uloženo v:
Podrobná bibliografie
Hlavní autoři: J Thompson Coon, M Hoyle, C Green, Z Liu, K Welch, T Moxham, K Stein
Médium: Artigo
Jazyk:Inglês
Vydáno: NIHR Journals Library 2010-01-01
Edice:Health Technology Assessment
Témata:
bevacizumab
sorafenib-tosylate
sunitinib
temsirolimus
renal-cell-carcinoma
systematic-review
economic-evaluation
On-line přístup:https://doi.org/10.3310/hta14020
Tagy: Přidat tag
Žádné tagy, Buďte první, kdo otaguje tento záznam!

Podobné jednotky